Lanean...
CDK4/6 Inhibitors in Cancer Therapy: A Novel Treatement Strategy for Bladder Cancer
Patients with metastatic bladder cancer (mBC) treated with cisplatin-based chemotherapy have a limited median survival of only around 14 months [1]. Despite over 30 years of basic and clinical research, until recently no therapeutic options beyond cisplatin-based therapy had entered clinical routine...
Gorde:
| Argitaratua izan da: | Bladder Cancer |
|---|---|
| Egile Nagusiak: | , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
IOS Press
2017
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5409046/ https://ncbi.nlm.nih.gov/pubmed/28516152 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3233/BLC-170105 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|